Sarepta Therapeutics diskutieren
Sarepta Therapeutics
WKN: A1J1BH / Symbol: AVII / Name: Sarepta / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
125,00 €
0,83 %
Kursziel geändert auf 140,0
- Sarepta Therapeutics (NASDAQ:SRPT) is up 13% premarket on entering into a licensing agreement with Roche (OTCQX:RHHBY), providing latter an exclusive commercial rights to SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the U.S.
- Under the agreement, Sarepta will receive $1.15B in an upfront payment and an equity investment; up to $1.7B in regulatory and sales milestones; and royalties on net sales in the mid-teens.
Buy beendet
Buy mit Kursziel 150,0
Buy Sarepta Therapeutics
Buy Sarepta Therapeutics
Sell Sarepta Therapeutics
Buy Sarepta Therapeutics
Buy Sarepta Therapeutics
Sell Sarepta Therapeutics
Buy Sarepta Therapeutics
Buy Sarepta Therapeutics
Kursziel geändert auf 170,0
Kursziel geändert auf 160,0
Sell Sarepta Therapeutics
Sell Sarepta Therapeutics
Sell Sarepta Therapeutics
Sell Sarepta Therapeutics
Buy Sarepta Therapeutics
Sell mit Kursziel 30,0
Neueste Beiträge
DrMabuse in Berkshire Hathaway Inc. B diskutieren